Internal Medicine · Honolulu, HI
NPI
1447328620
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2228 Liliha St, Suite #103
Honolulu, HI, 96817
Phone (808) 536-9326
Groups this clinician bills Medicare through
Medicare paid, 2024
$182K
2,641 services
Medicare patients, 2024
200
Average age 78
Drug cost, 2024
$2.0M
9,453 prescriptions
Company payments, 2025
$5,313
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas K Tan was code 99214 (office e&m - established), 898 times for 198 patients. In total Thomas K Tan billed 2,641 services in 12 codes, and Medicare paid $182K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-10-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 898 | 198 | $104.07 | $93K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 744 | 185 | $13.04 | $9,702 |
| 99213 Office E&M - Established | Office | 479 | 160 | $73.70 | $35K |
| 99497 Care Management/Coordination | Office | 189 | 187 | $64.30 | $12K |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 175 | 175 | $134.42 | $24K |
| 90656 Vaccine Product | Office | 48 | 48 | $21.90 | $1,051 |
| G0008 Administration of influenza virus vaccine | Office | 47 | 47 | $33.52 | $1,575 |
| 93000 Electrocardiogram | Office | 23 | 19 | $11.89 | $273 |
| 99205 Office E&M - New | Office | 16 | 16 | $159.86 | $2,558 |
By year: 2022 $141K for 1,511 services; 2023 $165K for 1,781 services; 2024 $182K for 2,641 services.
Medicare prescription drug claims, 2024
In 2024, the drug Thomas K Tan prescribed most often to Medicare patients was Atorvastatin Calcium, with 975 prescriptions and refills. In total Thomas K Tan wrote 9,453 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 975 | 2,641 | 277 | $16K |
| Amlodipine Besylate Generic | 565 | 1,574 | 161 | $5,665 |
| Losartan Potassium Generic | 530 | 1,491 | 154 | $6,392 |
| Metformin Hcl Generic | 393 | 1,065 | 108 | $2,657 |
| Farxiga Dapagliflozin Propanediol | 271 | 655 | 73 | $370K |
| Levothyroxine Sodium Generic | 268 | 764 | 72 | $2,212 |
| Simvastatin Generic | 260 | 706 | 67 | $4,560 |
| Vascepa Icosapent Ethyl | 227 | 558 | 67 | $185K |
| Omeprazole Generic | 205 | 415 | 94 | $3,927 |
| Rosuvastatin Calcium Generic | 194 | 566 | 58 | $7,478 |
| Metoprolol Succinate Generic | 190 | 475 | 51 | $2,257 |
| Allopurinol Generic | 176 | 456 | 48 | $2,036 |
| Olmesartan Medoxomil Generic | 174 | 510 | 48 | $10K |
| Pioglitazone Hcl Generic | 156 | 357 | 36 | $2,972 |
| Pravastatin Sodium Generic | 146 | 393 | 38 | $2,107 |
Brand drugs: 1,670 claims; generic drugs: 7,717 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas K Tan $5,313 ($5,313 in general payments such as food, travel and fees) from 19 companies. The largest payer was Amgen Inc. with $1,096.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 24 | $1,096 |
| Novo Nordisk Inc NVO | 16 | $727 |
| AstraZeneca Pharmaceuticals LP AZN | 20 | $687 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 13 | $567 |
| Abbott Laboratories ABT | 3 | $279 |
| Insulet Corporation PODD | 2 | $275 |
| Lilly USA, LLC LLY | 3 | $266 |
| Dexcom, Inc. DXCM | 2 | $255 |
| ANI Pharmaceuticals, Inc. ANIP | 3 | $183 |
| Gilead Sciences, Inc. GILD | 6 | $154 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.